Literature DB >> 28295019

M2e-tetramer-specific memory CD4 T cells are broadly protective against influenza infection.

D G Eliasson1, A Omokanye1, K Schön1, U A Wenzel1, V Bernasconi1, M Bemark1, A Kolpe2, K El Bakkouri2, T Ysenbaert2, L Deng2, W Fiers2, X Saelens2, N Lycke1.   

Abstract

Matrix protein 2 ectodomain (M2e) is considered an attractive component of a broadly protective, universal influenza A vaccine. Here we challenge the canonical view that antibodies against M2e are the prime effectors of protection. Intranasal immunizations of Balb/c mice with CTA1-3M2e-DD-generated M2e-specific memory CD4 T cells that were I-Ad restricted and critically protected against infection, even in the complete absence of antibodies, as observed in JhD mice. Whereas some M2e-tetramer-specific memory CD4 T cells resided in spleen and lymph nodes, the majority were lung-resident Th17 cells, that rapidly expanded upon a viral challenge infection. Indeed, immunized IL-17A-/- mice were significantly less well protected compared with wild-type mice despite exhibiting comparable antibody levels. Similarly, poor protection was also observed in congenic Balb/B (H-2b) mice, which failed to develop M2e-specific CD4 T cells, but exhibited comparable antibody levels. Lung-resident CD69+ CD103low M2e-specific memory CD4 T cells were αβ TCR+ and 50% were Th17 cells that were associated with an early influx of neutrophils after virus challenge. Adoptively transferred M2e memory CD4 T cells were strong helper T cells, which accelerated M2e- but more importantly also hemagglutinin-specific IgG production. Thus, for the first time we demonstrate that M2e-specific memory CD4 T cells are broadly protective.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28295019     DOI: 10.1038/mi.2017.14

Source DB:  PubMed          Journal:  Mucosal Immunol        ISSN: 1933-0219            Impact factor:   7.313


  92 in total

1.  Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans.

Authors:  Tom M Wilkinson; Chris K F Li; Cecilia S C Chui; Arthur K Y Huang; Molly Perkins; Julia C Liebner; Rob Lambkin-Williams; Anthony Gilbert; John Oxford; Ben Nicholas; Karl J Staples; Tao Dong; Daniel C Douek; Andrew J McMichael; Xiao-Ning Xu
Journal:  Nat Med       Date:  2012-01-29       Impact factor: 53.440

2.  Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit.

Authors:  L C Agren; L Ekman; B Löwenadler; N Y Lycke
Journal:  J Immunol       Date:  1997-04-15       Impact factor: 5.422

3.  Natural and long-lasting cellular immune responses against influenza in the M2e-immune host.

Authors:  M Schotsaert; T Ysenbaert; K Neyt; L I Ibañez; P Bogaert; B Schepens; B N Lambrecht; W Fiers; X Saelens
Journal:  Mucosal Immunol       Date:  2012-07-18       Impact factor: 7.313

4.  A common solution to group 2 influenza virus neutralization.

Authors:  Robert H E Friesen; Peter S Lee; Esther J M Stoop; Ryan M B Hoffman; Damian C Ekiert; Gira Bhabha; Wenli Yu; Jarek Juraszek; Wouter Koudstaal; Mandy Jongeneelen; Hans J W M Korse; Carla Ophorst; Els C M Brinkman-van der Linden; Mark Throsby; Mark J Kwakkenbos; Arjen Q Bakker; Tim Beaumont; Hergen Spits; Ted Kwaks; Ronald Vogels; Andrew B Ward; Jaap Goudsmit; Ian A Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-11       Impact factor: 11.205

5.  Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults.

Authors:  Christine B Turley; Richard E Rupp; Casey Johnson; David N Taylor; Julie Wolfson; Lynda Tussey; Uma Kavita; Lawrence Stanberry; Alan Shaw
Journal:  Vaccine       Date:  2011-05-30       Impact factor: 3.641

Review 6.  Soluble recombinant influenza vaccines.

Authors:  W Fiers; S Neirynck; T Deroo; X Saelens; W M Jou
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-12-29       Impact factor: 6.237

Review 7.  Influenza vaccines: challenges and solutions.

Authors:  Katherine Houser; Kanta Subbarao
Journal:  Cell Host Microbe       Date:  2015-03-11       Impact factor: 21.023

8.  Neutrophil trails guide influenza-specific CD8⁺ T cells in the airways.

Authors:  Kihong Lim; Young-Min Hyun; Kris Lambert-Emo; Tara Capece; Seyeon Bae; Richard Miller; David J Topham; Minsoo Kim
Journal:  Science       Date:  2015-09-04       Impact factor: 47.728

Review 9.  Multipronged CD4(+) T-cell effector and memory responses cooperate to provide potent immunity against respiratory virus.

Authors:  Tara M Strutt; K Kai McKinstry; Nikki B Marshall; Allen M Vong; Richard W Dutton; Susan L Swain
Journal:  Immunol Rev       Date:  2013-09       Impact factor: 12.988

10.  MHC class I-restricted cytotoxic lymphocyte responses induced by enterotoxin-based mucosal adjuvants.

Authors:  C P Simmons; P Mastroeni; R Fowler; M Ghaem-maghami; N Lycke; M Pizza; R Rappuoli; G Dougan
Journal:  J Immunol       Date:  1999-12-15       Impact factor: 5.422

View more
  32 in total

1.  Protein nanoparticle vaccine based on flagellin carrier fused to influenza conserved epitopes confers full protection against influenza A virus challenge.

Authors:  Lei Deng; Jong R Kim; Timothy Z Chang; Han Zhang; Teena Mohan; Julie A Champion; Bao-Zhong Wang
Journal:  Virology       Date:  2017-06-13       Impact factor: 3.616

Review 2.  Sentinels of the Type 2 Immune Response.

Authors:  Jakob von Moltke; Marion Pepper
Journal:  Trends Immunol       Date:  2017-11-06       Impact factor: 16.687

Review 3.  Distinct and complementary roles of CD4 T cells in protective immunity to influenza virus.

Authors:  Andrea J Sant; Katherine A Richards; Jennifer Nayak
Journal:  Curr Opin Immunol       Date:  2018-04-02       Impact factor: 7.486

Review 4.  Early programming and late-acting checkpoints governing the development of CD4 T-cell memory.

Authors:  Kunal Dhume; Karl Kai McKinstry
Journal:  Immunology       Date:  2018-05-21       Impact factor: 7.397

5.  ADP-ribosylating adjuvant reveals plasticity in cDC1 cells that drive mucosal Th17 cell development and protection against influenza virus infection.

Authors:  Mohammad Arabpour; Cristina Lebrero-Fernandez; Karin Schön; Anneli Strömberg; Vanja Börjesson; Katharina Lahl; Marlies Ballegeer; Xavier Saelens; Davide Angeletti; William Agace; Nils Lycke
Journal:  Mucosal Immunol       Date:  2022-04-13       Impact factor: 8.701

6.  A vaccine combination of lipid nanoparticles and a cholera toxin adjuvant derivative greatly improves lung protection against influenza virus infection.

Authors:  Valentina Bernasconi; Karin Norling; Inta Gribonika; Li Ching Ong; Sabina Burazerovic; Nagma Parveen; Karin Schön; Anneli Stensson; Marta Bally; Göran Larson; Fredrik Höök; Nils Lycke
Journal:  Mucosal Immunol       Date:  2020-08-17       Impact factor: 7.313

7.  Tetramerizing tGCN4 domain facilitates production of Influenza A H1N1 M2e higher order soluble oligomers that show enhanced immunogenicity in vivo.

Authors:  Sweety Samal; Tripti Shrivastava; Praveen Sonkusre; Zaigham Abbas Rizvi; Rajesh Kumar; Shubbir Ahmed; Preeti Vishwakarma; Naveen Yadav; Manish Bansal; Kanchana Chauhan; Sebanta Pokhrel; Supratik Das; Padmakar Tambare; Amit Awasthi
Journal:  J Biol Chem       Date:  2020-08-13       Impact factor: 5.157

Review 8.  Universal influenza vaccines: from viruses to nanoparticles.

Authors:  Ye Wang; Lei Deng; Sang-Moo Kang; Bao-Zhong Wang
Journal:  Expert Rev Vaccines       Date:  2018-11-02       Impact factor: 5.217

9.  Bona Fide Th17 Cells without Th1 Functional Plasticity Protect against Influenza.

Authors:  Kunal Dhume; Caroline M Finn; Priyadharshini Devarajan; Ayushi Singh; Joanne D Tejero; Emily Prokop; Tara M Strutt; Stewart Sell; Susan L Swain; Karl Kai McKinstry
Journal:  J Immunol       Date:  2022-03-25       Impact factor: 5.426

10.  Double-layered protein nanoparticles induce broad protection against divergent influenza A viruses.

Authors:  Lei Deng; Teena Mohan; Timothy Z Chang; Gilbert X Gonzalez; Ye Wang; Young-Man Kwon; Sang-Moo Kang; Richard W Compans; Julie A Champion; Bao-Zhong Wang
Journal:  Nat Commun       Date:  2018-01-24       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.